Digest Network Come funziona
Network
/
Società
Ke
Non verificato

Kezar Life Sciences, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

18 comunicati stampa

Guarda tutti i comunicati
12/11/2025
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Web e Social Network
Telefonia e Varie
Mercato azionario
Kezar Life Sciences Reports Third Quarter 2025 Financial Results
Fonte
Kezar Life Sciences, Inc.
Emittente
Business Wire
1.00
0
07/11/2025
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Eventi
Industria
Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) – The Liver Meeting® 2025
Fonte
Kezar Life Sciences, Inc.
Emittente
Business Wire
1.00
0
16/10/2025
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Igiene alimentare
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Industria
Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives
Fonte
Kezar Life Sciences, Inc.
Emittente
Business Wire
1.00
0
13/08/2025
Biotecnologia
Igiene alimentare
Salute
Farmaceutica
Medicina - Varie
Mercato azionario
Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update
Fonte
Kezar Life Sciences, Inc.
Emittente
Business Wire
1.00
0
15/07/2025
Salute
Igiene alimentare
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis
Fonte
Kezar Life Sciences, Inc.
Emittente
Business Wire
1.00
0
28/05/2025
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Medicina - Varie
Web e Social Network
Fiere
Eventi
Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference
Fonte
Kezar Life Sciences, Inc.
Emittente
Business Wire
1.00
0
13/05/2025
Mercato azionario
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update
Fonte
Kezar Life Sciences, Inc.
Emittente
Business Wire
1.00
0
25/03/2025
Web e Social Network
Telefonia e Varie
Industria
Mercato azionario
Biotecnologia
HIV, AIDS e malattie autoimmuni
Salute
Farmaceutica
Medicina - Varie
Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results
Fonte
Kezar Life Sciences, Inc.
Emittente
Business Wire
1.00
0
24/03/2025
Web e Social Network
Industria
Eventi
Scienza
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Sanità
Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025
Fonte
Kezar Life Sciences, Inc.
Emittente
Business Wire
1.00
0
18/02/2025
Web e Social Network
Eventi
Biotecnologia
HIV, AIDS e malattie autoimmuni
Salute
Farmaceutica
Medicina - Varie
Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025
Fonte
Kezar Life Sciences, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0